Hims & Hers Health
Connects personalized treatment plans with telehealth consultations and pharmacy fulfillment.
Something off on this page? Send us feedback.
Profile
Provides direct-to-consumer care across weight loss, hair regrowth, sexual health, dermatology, mental health, hormone health, and preventive testing. Recurring treatment plans connect digital intake, affiliated-provider consultations, prescriptions, and pharmacy fulfillment, with the United States as the core market and an expanded international footprint.
Sells personalized care for weight loss, hair regrowth, sexual health, dermatology and skincare, mental health, hormone health, and preventive testing through websites and mobile apps. Customers pay directly for prescription and nonprescription products, laboratory services, and recurring treatment plans that include provider follow-up.
Combines consumer marketing, digital intake, telehealth, electronic records, and predominantly owned-pharmacy fulfillment in one integrated operating model. The United States remains the core market; ZAVA, Livewell, and Eucalyptus extend the platform across the United Kingdom, Australia, Canada, parts of Europe, and Japan.
Clinical care in the United States is delivered by separately owned affiliated medical groups. Operations depend on licensed providers, pharmaceutical supply and fulfillment, and changing rules governing telehealth, prescribing, pharmacy practice, privacy, and compounded medications.
Company facts
Key statistics
Year to date −13.7% · Average volume (30d) 14.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 24, 2026 | Truist Financial | Target | $18 | $32 | |
| Aug 20, 2026 | Barclays | Reiterate | Overweight | $39 | $35 |
| Aug 11, 2026 | Deutsche Bank | Reiterate | Hold | $25 | $26 |
| Aug 11, 2026 | Needham | Reiterate | Buy | $30 | $42 |
| Aug 11, 2026 | Morgan Stanley | Reiterate | Equal Weight | $21 | $28 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$0.05 | −$0.37 | −643.1% | $698.9M | $753.2M | +7.8% | −3.97% |
| May 11, 2026Q1 FY26 | $0.04 | −$0.18 | −550.0% | $616.8M | $608.1M | −1.4% | −14.10% |
| Feb 23, 2026Q4 FY25 | $0.02 | $0.07 | +250.0% | $619.2M | $617.8M | −0.2% | −0.32% |
| Nov 3, 2025Q3 FY25 | $0.09 | $0.06 | −33.3% | $618.1M | $599.0M | −3.1% | −3.60% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $586.0M | $544.8M | $599.0M | $617.8M | $608.1M | $753.2M | |
| Gross profit | $430.7M | $416.2M | $442.1M | $444.4M | $300.3M | $480.8M | |
| Operating income | $57.9M | $26.7M | $11.8M | $9.2M | −$16.5M | −$97.2M | |
| Net income | $49.5M | $42.5M | $15.8M | $20.6M | −$92.1M | −$86.3M | |
| Diluted EPS | $0.20 | $0.17 | $0.06 | $0.08 | −$0.40 | −$0.37 | |
| Gross margin | 73.5% | 76.4% | 73.8% | 71.9% | 49.4% | 63.8% | |
| Operating margin | 9.9% | 4.9% | 2.0% | 1.5% | -2.7% | -12.9% |
Fiscal years (4-quarter sums)FY21 $271.9M · FY22 $526.9M · FY23 $872.0M · FY24 $1.48B · FY25 $2.35B
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $841.0M · Total debt $1.55B · Total assets $3.63B · Shareholders' equity $324.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 223.08M · Float 208.82M · 93.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 28.70M | 12.87% | 13F | Aug 7, 2026 |
| G1 Execution Services, LLC | 14.50M | 6.50% | 13G | May 15, 2026 |
| Vanguard Capital Management | 11.19M | 5.01% | 13G | Jul 31, 2026 |
| Vanguard Portfolio Management LLC | 10.56M | 4.73% | 13F | Aug 13, 2026 |
| State Street Corp | 8.15M | 3.65% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Soleil Boughton | officer: Chief Legal Officer | −25,111 | $27.55 |
| Aug 19, 2026 | Oluyemi Okupe | officer: Chief Financial Officer | −4,938 | $29.99 |
| Aug 18, 2026 | Deborah M. Autor | director, officer: Chief Policy Officer | −16,773 | $27.85 |
| Aug 17, 2026 | Oluyemi Okupe | officer: Chief Financial Officer | −9,388 | $27.89 |
| Jun 18, 2026 | Oluyemi Okupe | officer: Chief Financial Officer | −55,383 | $35.09 |
Peers
- LifeMD
Closest public DTC telehealth peer in weight loss and men's health
- GoodRx
Prescription-access platform moving into DTC condition subscriptions
- Teladoc Health
Virtual-care incumbent with integrated care and mental-health scale
- Novo Nordisk (ADR)
Branded semaglutide maker attacking compounded GLP-1 demand
- Amazon
Consumer-scale virtual care and pharmacy delivery challenger
- Eli Lilly
Tirzepatide leader using LillyDirect to bypass intermediaries
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Hims & Hers Health | $28.86 | +0.10% | $6.43B | — | 110.6 | 2.5 | +38.3% |
| LifeMD | $3.20 | +1.74% | $151.9M | — | — | 0.7 | −24.0% |
| GoodRx | $3.53 | −0.42% | $1.22B | 83.1 | 10.4 | 1.6 | −1.3% |
| Teladoc Health | $6.50 | 0.00% | $1.18B | — | — | 0.5 | −4.0% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Amazon | $266.10 | −0.11% | $2.87T | 21.4 | 28.5 | 3.7 | +19.6% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Median | 30.4 | 23.5 | 2.6 | −0.6% |